# Sanofi

法国制药领导者——重磅生物制品Dupixent和Warp Speed疫苗贡献；临床和商业生物制品大型CDMO客户；NASDAQ: SNY。

Source: https://cn.bioecon.ru/companies/sanofi/
Updated: 2026-06-19

- 国家: France
- 营收: €41.6B
- 员工: ~90,000 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 赛诺菲计划到2030年在美国投资至少$200亿。 (2025-05-14) | https://www.prnewswire.com/news-releases/sanofi-to-invest-at-least-20-billion-in-the-us-through-2030-growing-investments-in-science-and-expanding-domestic-manufacturing-302455566.html |
| 生产基地 | 赛诺菲在全球运营7个专科药基地、10个疫苗基地及23个普药基地。 (2025-03-20) | https://www.bioprocessintl.com/upstream-downstream-processing/adding-context-data-mapping-key-to-sanofi-s-digitization-strategy |
| 产能 | 全球制造网络年产20亿剂；美国业务年供应超过6亿件。 (2026-08-31) | https://www.sanofi.com/en/our-science/manufacturing-and-supply, https://www.sanofi.us/en/our-science/manufacturing-and-supply |
| 认证 | Neuville-sur-Saône基地按LEED认证标准设计。 (2024-05-13) | https://www.sanofi.com/assets/dotcom/pressreleases/2024/2024-05-13-05-00-00-2880074-en.pdf |
| 监管批准 | 2025年，赛诺菲在免疫学、罕见病及其他领域共获得十项监管批准。 (2025-12-31) | https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm |

独立来源: bioprocessintl.com, prnewswire.com, sec.gov

## 技术

- [异种生物学与扩展遗传字母表（XNA）](https://cn.bioecon.ru/technology/xenobiology-expanded-genetic-alphabet/)
- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [生物药 (Biologics)](https://cn.bioecon.ru/technology/biologics/)